ZyVersa Therapeutics Files Q1 2025 10-Q
Ticker: ZVSA · Form: 10-Q · Filed: May 12, 2025 · CIK: 1859007
| Field | Detail |
|---|---|
| Company | Zyversa Therapeutics, Inc. (ZVSA) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
ZyVersa Q1 2025 10-Q filed. Financials and stock details updated.
AI Summary
ZyVersa Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Larkspur Health Acquisition Corp., reported its financial status and business operations. Key financial data points and stock information are detailed within the filing.
Why It Matters
This filing provides investors with an update on ZyVersa Therapeutics' financial health and operational progress for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, ZyVersa Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- ZyVersa Therapeutics, Inc. (company) — Filer of the 10-Q
- Larkspur Health Acquisition Corp. (company) — Former name of ZyVersa Therapeutics, Inc.
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date
FAQ
What is the primary business of ZyVersa Therapeutics, Inc.?
ZyVersa Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
When was the company formerly known as Larkspur Health Acquisition Corp.?
The company changed its name from Larkspur Health Acquisition Corp. on April 26, 2021.
What is the fiscal year end for ZyVersa Therapeutics, Inc.?
The company's fiscal year ends on December 31.
What is the SEC file number for ZyVersa Therapeutics, Inc.?
The SEC file number is 001-41184.
What is the business address of ZyVersa Therapeutics, Inc.?
The business address is 217 W. MAIN STREET, SOMERVILLE, NJ 08876.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding ZyVersa Therapeutics, Inc. (ZVSA).